NCT01254045View on ClinicalTrials.gov

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

January 31, 2010

Conditions
Fragile X Syndrome
Interventions
DRUG

placebo

intranasal placebo (48 international units)

DRUG

oxytocin 24IU

intranasal oxytocin (24 international units) and intranasal placebo (24 international units)

DRUG

oxytocin 48IU

intranasal oxytocin (48 international units)

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT01254045 - Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome | Biotech Hunter | Biotech Hunter